Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.

Original languageEnglish (US)
Article number427863
JournalAdvances in Hematology
Volume2011
DOIs
StatePublished - 2011

Fingerprint

Graft vs Host Disease
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Transplants
Immunosuppressive Agents
Stromal Cells
Clinical Trials
Population
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology

Cite this

@article{aef1196a70c34177921887a529da577f,
title = "Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease",
abstract = "Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.",
author = "Yi Lin and William Hogan",
year = "2011",
doi = "10.1155/2011/427863",
language = "English (US)",
volume = "2011",
journal = "Advances in Hematology",
issn = "1687-9104",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease

AU - Lin, Yi

AU - Hogan, William

PY - 2011

Y1 - 2011

N2 - Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.

AB - Mesenchymal stem cells (MSCs) represent a heterogeneous population of stromal cells with pluripotent mesenchymal differentiation potential. They have been found to have immunosuppressive properties and the ability to modulate angiogenesis and endogenous tissue repair by in vitro and animal studies. Clinical trials have examined the utility of these cells in autoimmune and inflammatory conditions. In particular, in allogeneic hematopoietic stem cell transplant (HSCT), multiple studies have been conducted to explore the use of MSC to treat acute and chronic graft-versus-host disease (GVHD) and for cotransplantation with HSCT to promote HSC engraftment and prevent GVHD. We review here the results of these studies and discuss some challenges of this treatment modality in this disease setting.

UR - http://www.scopus.com/inward/record.url?scp=84862952653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862952653&partnerID=8YFLogxK

U2 - 10.1155/2011/427863

DO - 10.1155/2011/427863

M3 - Article

C2 - 22190941

AN - SCOPUS:84862952653

VL - 2011

JO - Advances in Hematology

JF - Advances in Hematology

SN - 1687-9104

M1 - 427863

ER -